Intellia Therapeutics (NTLA) Receivables - Other (2015 - 2023)
Intellia Therapeutics (NTLA) posted quarterly Receivables - Other of $1.0 million for Q4 2023, down 37.5% year-over-year from $1.6 million in Q4 2022, and little changed quarter-over-quarter from $1.0 million in Q3 2023.
Intellia Therapeutics (NTLA) Receivables - Other (2015 - 2023) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Receivables - Other for 9 consecutive years, with $1.0 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Receivables - Other fell 37.5% year-over-year to $1.0 million; the TTM figure through Dec 2023 stood at $1.0 million (down 37.5% YoY), while the FY2023 annual figure was $1.0 million, down 37.5% from the prior year.
- Receivables - Other held at $1.0 million in Q4 2023 per NTLA's latest filing, from $1.0 million in the prior quarter.
- Across five years, Receivables - Other topped out at $8.4 million in Q1 2020 and bottomed at $700000.0 in Q1 2023.
- Historically, Receivables - Other has averaged $2.2 million across 5 years, with a median of $1.5 million in 2022.
- Annual changes were most pronounced in 2020 — Receivables - Other surged 740.0% — and 2021, when it tumbled 88.1%.
- Intellia Therapeutics' Receivables - Other stood at $3.6 million in 2019, then sank by 41.67% to $2.1 million in 2020, then changed by 0.0% to $2.1 million in 2021, then dropped by 23.81% to $1.6 million in 2022, then plunged by 37.5% to $1.0 million in 2023.
- Business Quant data shows NTLA's Receivables - Other at $1.0 million in Q4 2023, $1.0 million in Q3 2023, and $1.4 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.00 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Sep 30, 2023 | 1.00 Mn |
| Sep 30, 2023 | 1.00 Mn |
| Jun 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 1.40 Mn |
| Mar 31, 2023 | 700,000.00 |
| Mar 31, 2023 | 700,000.00 |
| Dec 31, 2022 | 1.60 Mn |
| Dec 31, 2022 | 1.60 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Sep 30, 2022 | 4.00 Mn |
| Jun 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 2.90 Mn |
| Mar 31, 2022 | 1.80 Mn |
| Mar 31, 2022 | 1.80 Mn |
| Sep 30, 2021 | 2.10 Mn |
| Sep 30, 2021 | 2.10 Mn |
| Mar 31, 2021 | 1.00 Mn |
| Mar 31, 2021 | 1.00 Mn |